WASHINGTON — Despite a withering 4-plus hours of questioning by members of a congressional committee yesterday, Mylan CEO Heather Bresch did not give a direct answer as to why the company had ...

Senators Question Mylan CEO Over EpiPen Pricing, Generic Plans A group of 20 Senate democrats on Tuesday sent a letter to Mylan CEO Heather Bresch, questioning her about her company's actions in ...

Mylan CEO Heather Bresch on Thursday defended the more than 400% price increase for its life-saving EpiPen, saying the company has made the device “more ergonomic” and that patients “never see the ...

When Mylan CEO Heather Bresch testified before the House Oversight Committee Sept. 21, she told lawmakers the company makes $100 in profit off a two-pack of EpiPens listed at $608. However, Ms. Bresch ...

WASHINGTON -- Outraged Republican and Democratic lawmakers Wednesday grilled the head of pharmaceutical company Mylan about the significant cost increase of its life-saving EpiPens and the profits for ...

The controversy surrounding the cost of EpiPen’s did not stop Fortune from including Mylan CEO Heather Bresch on its “Most Powerful Women” list for 2016. Ms. Bresch faced large backlash in the past ...

Lawmakers are imploring Mylan Pharmaceutical, the manufacturer of EpiPens, to scale back price increases that have seen the cost of the life-saving emergency allergy treatment swell from $100 to $600 ...

Heather Bresch will face the proverbial lash from Congress on Wednesday over the escalating cost of Mylan NV’s EpiPen. Her boss won’t. Robert J. Coury acquired the rights to sell the emergency allergy ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Wells Fargo CEO John Stumpf drew fire from the Senate ...

Theravance Biopharma, Inc. (NASDAQ: TBPH) and Mylan Inc. (NASDAQ: MYL) today announced that the two companies will partner on the development and, subject to FDA approval, commercialization of TD-4208 ...